Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement
The U.S. Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. More than twice as many atopic dermatitis patients with uncontrolled moderate-to-severe hand and/or foot […]